EuclidSR Partners
Successful venture investing combines two essential components: finding opportunities with significant growth potential and helping to
Business Model:
Revenue: $7.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed EuclidSR Partners Information
Geographic Data
Address: Box 68
City: Dover
State: DE
Zip: 19904
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Successful venture investing combines two essential components: finding opportunities with significant growth potential and helping to deliver on that potential. It requires a committed approach by experienced investors, not just to building returns but to building companies. Successful investors - armed with deep knowledge of their industries - commit time and focus in addition to capital. EuclidSR Partners (ESR) provides this kind of commitment - a dedicated approach to life sciences, technology and their convergence, by a highly regarded team of industry experts. We look to find opportunities with significant growth potential and we work to unlock that potential for our investors. ESR possesses the elements critical for success in today&s;s venture capital environment
Contact Phone:
+12122186880
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2005 | SkinMedica | Series E | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 12/2002 | Catalyst Bioscience | Venture Round | 46M |
| 3/2001 | Plateau Systems | Private Equity Round | 18M |
| 5/2004 | Xan3D Technologies | Series C | 15.2M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 1/2007 | Standard BioTools | Series E | 0 |
| 11/2001 | Standard BioTools | Series C | 34M |
| 3/2001 | Acurian | Series B | 27M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 11/2020 | VIVUS | Post-IPO Equity | 33.6M |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 3/2004 | iJET International | Series C | 0 |
| 6/2001 | iJET International | Series B | 8.1M |
| 1/2002 | Melinta Therapeutics | Series A | 22M |
| 1/2002 | Xan3D Technologies | Series B | 40M |
| 1/1999 | Message Pharmaceuticals | Venture Round | 6.3M |
| 11/2020 | VIVUS | Post-IPO Equity | 0 |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 1/2009 | Melinta Therapeutics | Series D | 0 |
| 1/2007 | Standard BioTools | Series E | 0 |
| 6/2006 | Melinta Therapeutics | Series C | 0 |
| 4/2006 | SkinMedica | Series E | 0 |
| 9/2005 | Standard BioTools | Series D | 0 |
| 4/2005 | SkinMedica | Series E | 0 |
| 5/2004 | Xan3D Technologies | Series C | 0 |
| 3/2004 | iJET International | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
